PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma

December 19, 2022 12:39 pm Published by

Corrales, E., E. Levit-Zerdoun, P. Metzger, R. Mertes, A. Lehmann, J. Munch, S. Lemke, S. Kowar, and M. Boerries. 2022. PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma. Cell Commun Signal 20: 187. doi: 10.1186/s12964-022-00989-y.

Categorised in:

This post was written by Heike Ufheil